Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Aug;6(3):43-7.
doi: 10.17305/bjbms.2006.3143.

Immunosuppressive therapy protocols in kidney transplantation in adults

Jasenko Karamehić  1 , Marc Lorber, Richard Formica, Faris Gavrankapetanović, Bećir Heljić, Demo Subasić, Lamija Zecević
Affiliations
Review

Immunosuppressive therapy protocols in kidney transplantation in adults

Jasenko Karamehić et al. Bosn J Basic Med Sci. 2006 Aug.

Abstract

In practical terms, regardless of HLA compatibility level, whenever tissues are transplanted from one person to another it is essential to suppress the immune response of the recipient. A variety of methods are available however, the most frequently used ones have the disadvantage of being immunologicaly non specific. The consequence is a difficult balance between immunosuppression sufficient to prevent the tissue rejection and maintenance of immune system at the level of ability to adequately deal with an infection. The goal, not yet achieved, is to find a way of generating donor specific immunosuppression that leaves the immune machinery otherwise completely intact. The major approaches to immunosuppression are described below.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Vascular rejection in kidney transplant (Acute rejection).
FIGURE 2
FIGURE 2
Acute tubulitis (Acute rejection).
FIGURE 3
FIGURE 3
Transplant glomerulopathy with slight mesangial matrix increase in transplant nephropathy (Acute rejection).
FIGURE 4
FIGURE 4
Transplant glomerulopathy with no mesangial matrix increase (Acute rejection).
FIGURE 5 and 6
FIGURE 5 and 6
PAS positive nodular hyaline thickening in CsA toxicity in kidney transplant (Chronic rejection)
See this image and copyright information in PMC

References

    1. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter study. Lancet. 2000;356:194–198. - PubMed
    1. MacDonald AS. A worldwide phase III randomized, controlled safety and efficacy study of a sirolimus cyclosporine regimen for prevention of acute rejection in recipients of primary renal al-lografts. Transplantation. 2001;71:271–278. - PubMed
    1. Woodle ES, Vincenti FA. multicenter, open label pilot study of early (5 day) corticosteroid cessation in de novo renal transplant recipients under simulect, tacrolimus, and sirolimus therapy: interim analysis. Am. J. Transplantation. 2003;3:440–444.
    1. Formica RN, Friedman AL, Lorber MI. Evolving role of sirolimus immunosuppression after organ transplantation. Current Opinion in Organ Transplantation. 2002;7:353–357.
    1. Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation. 2005;11:1553–1560. - PubMed

Substances